Home » Stocks » FIXX

Homology Medicines, Inc. (FIXX)

Stock Price: $13.04 USD -0.55 (-4.05%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
After-hours: $13.25 +0.21 (1.61%) Jan 26, 6:58 PM
Market Cap 590.25M
Revenue (ttm) 2.29M
Net Income (ttm) -123.07M
Shares Out 45.23M
EPS (ttm) -2.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $13.04
Previous Close $13.59
Change ($) -0.55
Change (%) -4.05%
Day's Open 13.69
Day's Range 13.01 - 13.92
Day's Volume 228,645
52-Week Range 8.92 - 22.04

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 1 month ago

Homology Medicines is a US-based genetic medicines biotech company aiming to treat rare genetic diseases with an unmet medical need. Homology Medicines has a pipeline of 1 Phase 1/2 therapeuti...

Zacks Investment Research - 2 months ago

Homology Medicines (FIXX) delivered earnings and revenue surprises of 23.46% and 126.80%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for t...

GlobeNewsWire - 2 months ago

- Based on Positive Data , Advancing pheNIX Gene Therapy Clinical Trial for PKU to Dose Expansion Phase -

InvestorPlace - 2 months ago

Homology Medicines (FIXX) is making news on Monday after announcing a massive $60 million investment deal with Pfizer (PFE) The post Homology Medicines News: 9 Things for FIXX Stock Investors ...

GlobeNewsWire - 2 months ago

- Marked Reductions in Phe Observed at Two Dose s -

GlobeNewsWire - 2 months ago

Homology Webcast / Conference Call Scheduled for Friday, November 6 at 4:30 p.m. ET

Zacks Investment Research - 2 months ago

Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Newsfile Corp - 2 months ago

San Francisco, California--(Newsfile Corp. - October 29, 2020) - Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors with significant losses to submit your losses now. The fi...

Newsfile Corp - 2 months ago

San Francisco, California--(Newsfile Corp. - October 27, 2020) - Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors with significant losses to submit your losses now. The fi...

GlobeNewsWire - 3 months ago

HMI-203 Leverages Ability to Cross Blood-Brain-Barrier Following I.V. Administration, and Preclinical Data Show ed Improvements in Key Disease Biomarkers

Newsfile Corp - 3 months ago

Los Angeles, California--(Newsfile Corp. - October 21, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of invest...

Newsfile Corp - 3 months ago

San Francisco, California--(Newsfile Corp. - October 20, 2020) - Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors with significant losses to submit your losses now. The fi...

Newsfile Corp - 3 months ago

San Francisco, California--(Newsfile Corp. - October 16, 2020) -  Hagens Berman urges Homology Medicines, Inc. (NASDAQ: FIXX) investors with significant losses to submit your losses now. The f...

Business Wire - 3 months ago

LOS ANGELES--(BUSINESS WIRE)---- $FIXX #FIXX--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Homology Medicines, Inc.

Business Wire - 3 months ago

LOS ANGELES--(BUSINESS WIRE)---- $FIXX #classaction--The Law Offices of Frank R. Cruz continues its investigation of Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) on be...

Newsfile Corp - 3 months ago

New York, New York--(Newsfile Corp. - October 15, 2020) - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders...

Business Wire - 3 months ago

LOS ANGELES--(BUSINESS WIRE)---- $FIXX #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Homology Medicines, Inc. (FIXX) on Behalf of I...

Business Wire - 3 months ago

BENSALEM, Pa.--(BUSINESS WIRE)---- $FIXX #CLASSACTIONS--INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors

Business Wire - 3 months ago

BENSALEM, Pa.--(BUSINESS WIRE)---- $FIXX #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors

Business Wire - 3 months ago

LOS ANGELES--(BUSINESS WIRE)---- $FIXX #classaction--The Law Offices of Frank R. Cruz announces an investigation of Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) on beh...

Business Wire - 3 months ago

LOS ANGELES--(BUSINESS WIRE)---- $FIXX #FIXX--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Homology Medicines, Inc.

Business Wire - 3 months ago

LOS ANGELES--(BUSINESS WIRE)---- $FIXX #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Homology Medicines, Inc. (FIXX) on Behalf of I...

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Homology Medicines, Inc. (N...

GlobeNewsWire - 4 months ago

BEDFORD, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following virt...

Zacks Investment Research - 5 months ago

Homology Medicines (FIXX) delivered earnings and revenue surprises of 3.70% and 20.64%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

Three Cohorts Enrolled in Phase 1/2 pheNIX Gene Therapy Trial for PKU

Zacks Investment Research - 5 months ago

Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 6 months ago

- Executive with Extensive Rare Disease Expertise in Global Finance and  Commercial Operations -

Zacks Investment Research - 6 months ago

Homology Medicines (FIXX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

GlobeNewsWire - 8 months ago

 -  Methods Showed Efficient On-Target Gene Integration with No Unintended DNA Modifications -

Kiplinger - 8 months ago

Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.

Other stocks mentioned: ATRA, DVAX, GTHX, IMGN, KDMN, VKTX
GlobeNewsWire - 8 months ago

- Molecular Methods Quantified Precision and Efficiency of Nuclease-Free Gene Editing  for PKU -

Zacks Investment Research - 9 months ago

Homology Medicines (FIXX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

GlobeNewsWire - 10 months ago

- Data Package Supported Initiation of Ongoing pheNIX Clinical Trial for  Adults with PKU -

Zacks Investment Research - 10 months ago

Homology Medicines (FIXX) delivered earnings and revenue surprises of 23.61% and 40.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the...

Benzinga - 1 year ago

Shares of genetic therapy company Homology Medicines Inc (NASDAQ: FIXX) were moving to the downside Wednesday.

GlobeNewsWire - 1 year ago

- Well-Tolerated in First-in-Human AAVHSC Gene Therapy Trial -

GlobeNewsWire - 1 year ago

- Experienced Clinical Geneticist with Track Record in Rare Disease Drug Development Joins Homology’s Senior Management - 

GlobeNewsWire - 1 year ago

BEDFORD, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today a peer-reviewed publication demonstrating its propriet...

Zacks Investment Research - 1 year ago

Homology Medicines (FIXX) delivered earnings and revenue surprises of -15.52% and 17.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for t...

Zacks Investment Research - 1 year ago

Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

AAVHSCs Showed Consistent Therapeutic Effect Across All Empty to Full Capsid Ratios, and Improved Benefit in the PKU Murine Model Compared to AAV5 AAVHSCs Showed Consistent Therapeutic Effect ...

GlobeNewsWire - 1 year ago

BEDFORD, Mass., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the presentation of preclinical data that support its ...

GlobeNewsWire - 1 year ago

BEDFORD, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today presentations at the following industry, investor and...

GlobeNewsWire - 1 year ago

BEDFORD, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will participate in two upcom...

Zacks Investment Research - 1 year ago

Homology Medicines (FIXX) delivered earnings and revenue surprises of -16.36% and -73.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the ...

Zacks Investment Research - 1 year ago

Homology Medicines (FIXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About FIXX

Homology Medicines, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, cen... [Read more...]

Industry
Biotechnology
Founded
2015
CEO
Arthur Tzianabos
Employees
206
Stock Exchange
NASDAQ
Ticker Symbol
FIXX
Full Company Profile

Financial Performance

In 2019, FIXX's revenue was $1.67 million, a decrease of -68.70% compared to the previous year's $5.32 million. Losses were -$103.92 million, 87.0% more than in 2018.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for FIXX stock is "Strong Buy." The 12-month stock price forecast is 28.44, which is an increase of 118.10% from the latest price.

Price Target
$28.44
(118.10% upside)
Analyst Consensus: Strong Buy